- Home
- RVT vs PRAX Comparison
RVT vs PRAX Comparison
Compare RVT & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVT
- PRAX
- Stock Information
- Founded
- RVT 1986
- PRAX 2015
- Country
- RVT United States
- PRAX United States
- Employees
- RVT N/A
- PRAX N/A
- Industry
- RVT Trusts Except Educational Religious and Charitable
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- RVT Finance
- PRAX Health Care
- Exchange
- RVT Nasdaq
- PRAX Nasdaq
- Market Cap
- RVT 1.8B
- PRAX 1.5B
- IPO Year
- RVT N/A
- PRAX 2020
- Fundamental
- Price
- RVT $15.73
- PRAX $76.79
- Analyst Decision
- RVT
- PRAX Strong Buy
- Analyst Count
- RVT 0
- PRAX 9
- Target Price
- RVT N/A
- PRAX $146.33
- AVG Volume (30 Days)
- RVT 243.4K
- PRAX 393.5K
- Earning Date
- RVT 01-01-0001
- PRAX 11-06-2024
- Dividend Yield
- RVT 7.32%
- PRAX N/A
- EPS Growth
- RVT N/A
- PRAX N/A
- EPS
- RVT 2.95
- PRAX N/A
- Revenue
- RVT N/A
- PRAX $1,605,000.00
- Revenue This Year
- RVT N/A
- PRAX N/A
- Revenue Next Year
- RVT N/A
- PRAX N/A
- P/E Ratio
- RVT $4.98
- PRAX N/A
- Revenue Growth
- RVT N/A
- PRAX N/A
- 52 Week Low
- RVT $11.85
- PRAX $19.61
- 52 Week High
- RVT $14.93
- PRAX $86.93
- Technical
- Relative Strength Index (RSI)
- RVT 42.13
- PRAX 51.17
- Support Level
- RVT $15.16
- PRAX $68.42
- Resistance Level
- RVT $16.08
- PRAX $73.49
- Average True Range (ATR)
- RVT 0.29
- PRAX 4.62
- MACD
- RVT -0.16
- PRAX -0.06
- Stochastic Oscillator
- RVT 32.29
- PRAX 63.02
About RVT Royce Value Trust Inc.
Royce Value Trust Inc is a diversified closed-end investment company. It invests in diversified sectors including consumer discretionary, consumer staples, healthcare, financial, IT, telecommunications, and materials. The company's portfolio includes common stocks, preferred stocks, corporate bonds, and repurchase agreements.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.